THIOPURINES AND THEIR OPTIMISATION DURING INFLIXIMAB
INDUCTION AND MAINTENANCE: A RETROSPECTIVE STUDY IN CROHN’S
DISEASE

Raphael P. Luber MBBS FRACP\textsuperscript{1,2,*}, Luke Dawson MBBS\textsuperscript{1}, Stephanie Munari MBBS\textsuperscript{1},
Viraj C. Kariyawasam PhD FRACP\textsuperscript{3,4}, Catherine Martin PhD\textsuperscript{2}, Peter R. Gibson MD
FRACP\textsuperscript{1,2}, Miles P. Sparrow MBBS FRACP\textsuperscript{1,2}, Mark G. Ward MD FRACP\textsuperscript{1,2}

1. Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia
2. Monash University, Melbourne, Australia
3. Department of Gastroenterology, Concord Hospital, Sydney, Australia
4. University of Sydney, Sydney, Australia

* Current institution is Guy’s and St Thomas’ NHS foundation trust, London, United Kingdom

Running title: Thiopurine & infliximab combination therapy in Crohn’s

Correspondence: Dr Raphael Luber. Department of Gastroenterology, Guy’s and St. Thomas’ NHS Foundation Trust, Westminster Bridge Road, Lambeth, London SE1 7EH. +442071887188. raphaelluber@gmail.com

Disclosures:

RPL has received educational grants from Ferring, Pfizer and Vifor Pharma. VCK is on the advisory board of Janssen and has received research grants from Ferring, Abbvie, Takeda and Janssen. PRG has served as consultant or advisory board member for Allergan, Janssen, MSD, Pfizer, Anatara, Atmo Biosciences, Immunec Therapeutics, Novoymes and Takeda. His institution has received speaking honoraria from Janssen, Shire, Bristol-Meyers Squibb and Pfizer. He has received research grants for investigator-driven studies from MSD. He holds shares in Atmo Biosciences. His Department financially benefits from the sales of a digital application and booklets on the FODMAP diet. He has published two educational/recipe books on diet. MPS has received educational grants or research support from Ferring and Orphan, speaker’s fees from Janssen, Abbvie, Ferring, Takeda, Pfizer and Shire, and has served on advisory boards for Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD and Emerge Health. MGW has received educational grants or research support from AbbVie, the Ferring GESA IBD Clinical Project Award, and received speaker fees from Janssen,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jgh.15245

This article is protected by copyright. All rights reserved.